TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS
One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably where the metabolic disorder is one or more selected from ketoacidosis, pre-diabetes, insulin dependent diabetes me...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
01.12.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably where the metabolic disorder is one or more selected from ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or musculoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or musculoskeletal disorders, is prevented or progression is slowed or remission is achieved. |
---|---|
AbstractList | One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably where the metabolic disorder is one or more selected from ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or musculoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or musculoskeletal disorders, is prevented or progression is slowed or remission is achieved. |
Author | KLEY, Saskia REICHE, Dania |
Author_xml | – fullname: REICHE, Dania – fullname: KLEY, Saskia |
BookMark | eNrjYmDJy89L5WQwCglydQzxdfULUfB3U_B1DXF08vfxdFZw8Qz2D3JxDQpW8PRTcHb08_RzVQCSvo4-wTwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD402MjAyMjY3MLc2NzR0Jg4VQAKZilv |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
ExternalDocumentID | US2022378737A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_US2022378737A13 |
IEDL.DBID | EVB |
IngestDate | Fri Oct 04 05:00:47 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_US2022378737A13 |
Notes | Application Number: US202217873638 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221201&DB=EPODOC&CC=US&NR=2022378737A1 |
ParticipantIDs | epo_espacenet_US2022378737A1 |
PublicationCentury | 2000 |
PublicationDate | 20221201 |
PublicationDateYYYYMMDD | 2022-12-01 |
PublicationDate_xml | – month: 12 year: 2022 text: 20221201 day: 01 |
PublicationDecade | 2020 |
PublicationYear | 2022 |
RelatedCompanies | Boehringer Ingelheim Vetmedica GmbH |
RelatedCompanies_xml | – name: Boehringer Ingelheim Vetmedica GmbH |
Score | 3.442771 |
Snippet | One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder in a... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221201&DB=EPODOC&locale=&CC=US&NR=2022378737A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8Mw8BhT1Dedih9TAsreitv6ZR-GdGnKKms7-iF7G03agiDdcBX_vte46Z72EpIcXD7IfSV3F4BHXej9TM0KhXORKxpvgpUtbiqi0Hnf4JmWy9gqPzAmqfY61-ct-NjGwsg8od8yOSJSlEB6ryW_Xv1fYjnSt3L9xN-xa_niJiOnt7GOh8iI0TZ2xiM2C52Q9igdpXEviCRMxcOpmjbaSgeNIt1k2mdv4yYuZbUrVNxTOJwhvqo-g1ZRdeCYbv9e68CRv3nyxuqG-tbnMEwiZidN9n0SusRniT0Opx4ljhejKceimHgBoXbgBYxg6dvT-AIeXJbQiYKDL_7Wukjj3Zmql9CullVxBcSwhrmZPQ-KzCq1vES9SzWFWaLCog1KYajX0N2H6WY_-BZOmuavn0YX2vXnV3GH0rbm93KTfgCexn32 |
link.rule.ids | 230,309,786,891,25594,76903 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5KFetNq2K16oKSW7DN0x6KpJuERvMoSSq9hWweIEhabMS_72RttadelmUH9sXO49udmQV4UDN1kMppITKW5aLCmmDlEdPFrFDZQGOpkvPYKs_XpnPlZaEuWvCxjYXheUK_eXJE5KgM-b3m8nr1f4llct_K9SN7x6blsx2PTWGDjiUUxIiNzcnYmgVmQAVKx_NI8ENOk_FwyrqBWOlAR1DIwdLbpIlLWe0qFfsEDmfYX1WfQquoutCh27_XunDkbZ68sbrhvvUZSHFoGXGTfZ8ENvGs2JgErkOJ6UQI5awwIo5PqOE7vkWw9Aw3Ood724rpVMTBk7-1JvNod6byBbSrZVVcAtFGUq6nT8MiHZVKXqLdJeuZXqLBogzLTJN70N_X09V-8h10prHnJq7jv17DcUP69dnoQ7v-_CpuUPPW7JZv2A-nzIDg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=TREATMENT+OF+METABOLIC+DISORDERS+IN+CANINE+ANIMALS&rft.inventor=REICHE%2C+Dania&rft.inventor=KLEY%2C+Saskia&rft.date=2022-12-01&rft.externalDBID=A1&rft.externalDocID=US2022378737A1 |